Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early postoperative complication profile and acute hypothalamic dysfunction grading after surgery for adult intraventricular craniopharyngiomas: a single-center retrospective cohort study.

Langenbeck's archives of surgery·2026
Same author

Clinical, Radiological, and Immunohistological Distinctions Between Limbic-Predominant and Typical Alzheimer's Disease: A Systematic Review.

Brain and behavior·2026
Same author

The effect of Vitamin D and Vitamin D-based therapies on hemorrhage risk in cerebral cavernous malformations: A systematic review.

Surgical neurology international·2026
Same author

Crescentic "Semilunar" Cap-Like Pus-Fluid Level in Bacterial-Fungal Brain Abscess.

Clinical case reports·2026
Same author

A systematic review of penetrating injuries to the superior sagittal sinus across two centuries.

Frontiers in neurology·2026
Same author

Intratumoral hemorrhage in vestibular schwannomas post-radiosurgery: a systematic review.

Chinese neurosurgical journal·2026

Related Experiment Video

Updated: Jul 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-Analysis.

Kayode Agboola1,2, Fatemeh Khafaji3, Bipin Chaurasia4

  • 1Facharztzentrum for Surgery and Orthopaedics, Essen, Germany.

Brain and Behavior
|April 29, 2026
PubMed
Summary

Bevacizumab (BEV) monotherapy shows promise for recurrent glioblastoma multiforme (rGBM), improving outcomes like progression-free survival. Temozolomide (TMZ) also outperformed combination therapy for rGBM.

Keywords:
adverse eventsbevacizumab (BEV)glioblastoma multiforme (GBM)lomustine (CCNU)meta‐analysisoverall survival (OS)progression‐free survival (PFS)temozolomide (TMZ)

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

20.5K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

119

Related Experiment Videos

Last Updated: Jul 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

20.5K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

119

Area of Science:

  • Neuro-oncology
  • Clinical pharmacology
  • Evidence-based medicine

Background:

  • Glioblastoma multiforme (GBM) presents significant therapeutic challenges with high recurrence rates.
  • Limited effective treatment options necessitate novel strategies for recurrent GBM (rGBM).

Purpose of the Study:

  • To evaluate the efficacy and safety of bevacizumab (BEV), temozolomide (TMZ), and lomustine (CCNU) for rGBM.
  • To identify optimal treatment approaches for recurrent glioblastoma.

Main Methods:

  • Systematic review and meta-analysis adhering to PRISMA guidelines.
  • Inclusion of randomized controlled trials for rGBM interventions.
  • Assessment of progression-free survival (PFS), overall survival (OS), and adverse events using Cochrane risk-of-bias tool.

Main Results:

  • Bevacizumab (BEV) monotherapy demonstrated superior outcomes compared to pre-BEV treatments, including improved biopsy results and progression-free survival (PFS).
  • Temozolomide (TMZ) showed better PFS and MGMT promoter methylation rates than the TMZ + CCNU combination.
  • BEV monotherapy was associated with more favorable corticosteroid use and fewer CNS hemorrhages compared to combination therapies.

Conclusions:

  • Bevacizumab (BEV) monotherapy is a promising treatment for recurrent glioblastoma, enhancing biopsy results, corticosteroid use, PFS, and OS.
  • Further research is warranted to optimize BEV's clinical application and personalize treatment strategies for rGBM patients.